Neimeth International Pharmaceuticals Plc

NGSE:NEIMETH Stock Report

Market Cap: ₦8.5b

Neimeth International Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

J. Valentine Okelu

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.3yrs
CEO ownershipn/a
Management average tenure2.9yrs
Board average tenure10.1yrs

Recent management updates

Recent updates

CEO

J. Valentine Okelu

1.3yrs

Tenure

Pharm. J. Valentine C. Okelu served as Executive Director of Sales and Marketing at May & Baker Nigeria plc until August 2023 and also served as Executive Director of Corporate Planning & Strategy since Ju...

Leadership Team

NamePositionTenureCompensationOwnership
J. Valentine Okelu
MD, CEO & Director1.3yrsno datano data
Florence Onyenekwe
Executive Director of Finance5.9yrsno datano data
Roseline Oputa
Executive Director of Administration & Executive Director2.9yrsno datano data

2.9yrs

Average Tenure

Experienced Management: NEIMETH's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
J. Valentine Okelu
MD, CEO & Director1.3yrsno datano data
Roseline Oputa
Executive Director of Administration & Executive Director7.2yrsno datano data
Ambrosie Bryant Orjiako
Non-Executive Chairman20.8yrsno datano data
Mazi Sam Ohuabunwa
Non Executive Directorno datano datano data
Christopher Oshiafi
Non-Executive Directorno datano datano data
Thomas Osobu
Non Executive Director13yrsno datano data
Ikechukwu Onyechi
Non Executive Director13yrsno datano data
Maurice Iwu
Non Executive Director13yrsno datano data
Atinuke Uwajeh
Non-Executive Director1.3yrsno datano data
Olusegun Akanji
Non-Executive Director1.3yrsno datano data

10.1yrs

Average Tenure

Experienced Board: NEIMETH's board of directors are seasoned and experienced ( 10.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 09:06
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Neimeth International Pharmaceuticals Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullMeristem Securities Limited